Suppr超能文献

基于信息通信技术的夜间家庭血压监测评估缬沙坦联合西尼地平或氢氯噻嗪对家庭晨峰血压的影响。

Comparative effects of valsartan plus either cilnidipine or hydrochlorothiazide on home morning blood pressure surge evaluated by information and communication technology-based nocturnal home blood pressure monitoring.

机构信息

Jichi Medical University School of Medicine, Shimotsuke, Japan.

Higashiagatsuma-machi National Health Insurance Clinic, Gunma, Japan.

出版信息

J Clin Hypertens (Greenwich). 2018 Jan;20(1):159-167. doi: 10.1111/jch.13154. Epub 2018 Jan 5.

Abstract

The authors tested the hypothesis that a valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension, defined as systolic BP (SBP) ≥135 mm Hg or diastolic BP ≥85 mm Hg assessed by a self-measuring information and communication technology-based home BP monitoring device more than three times before either combination's administration. This was an 8-week prospective, multicenter, randomized, open-label clinical trial. The HMBPS, which is a new index, was defined as the mean morning SBP minus the mean nocturnal SBP, both measured on the same day. The authors randomly allocated 129 patients to the valsartan/cilnidipine (63 patients; mean 68.4 years) or valsartan/hydrochlorothiazide (66 patients; mean 67.3 years) combination groups, and the baseline HMBPS values were 17.4 mm Hg vs 16.9 mm Hg, respectively (P = .820). At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively. HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892). Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide. Large-scale randomized controlled studies are needed to assess how reducing HMBPS will affect future cardiovascular outcomes. The information and communication technology-based home BP monitoring device may become an alternative to ambulatory BP monitoring, which has been a gold standard to measure nocturnal BP and the morning BP surge.

摘要

作者检验了以下假设,即在早上高血压患者中,与缬沙坦/氢氯噻嗪联合治疗相比,缬沙坦/西尼地平联合治疗能更有效地抑制清晨血压高峰(HMBPS),这些患者的清晨血压由自我测量信息和通信技术(ICT)为基础的家庭血压监测设备评估,在开始使用两种联合药物治疗前三次以上,收缩压(SBP)≥135mmHg 或舒张压(DBP)≥85mmHg。这是一项为期 8 周的前瞻性、多中心、随机、开放标签临床试验。HMBPS 是一个新的指标,定义为同一天测量的清晨 SBP 平均值减去夜间 SBP 平均值。作者将 129 名患者随机分配至缬沙坦/西尼地平(63 名患者;平均年龄 68.4 岁)或缬沙坦/氢氯噻嗪(66 名患者;平均年龄 67.3 岁)联合治疗组,基线 HMBPS 值分别为 17.4mmHg 与 16.9mmHg(P=.820)。在治疗期末,缬沙坦/西尼地平组和缬沙坦/氢氯噻嗪组夜间 SBP 和清晨 SBP 与基线相比均有显著变化(P<0.001):-5.0mmHg 与-10.0mmHg(P=.035)和-10.7mmHg 与-13.6mmHg(P=.142)。两组 HMBPS 与基线相比均有显著下降(P<0.001),但两组之间无显著差异:分别为 14.4mmHg 与 14.0mmHg(P=.892)。与缬沙坦/氢氯噻嗪相比,缬沙坦/西尼地平并不能显著抑制 HMBPS。需要进行大规模的随机对照研究来评估降低 HMBPS 对未来心血管结局的影响。基于 ICT 的家庭血压监测设备可能成为动态血压监测的替代方法,后者一直是测量夜间血压和清晨血压高峰的金标准。

相似文献

引用本文的文献

4
Clinical studies on pharmacological treatment of hypertension in Japan.日本高血压药物治疗的临床研究。
J Hum Hypertens. 2024 Jun;38(6):486-499. doi: 10.1038/s41371-021-00533-4. Epub 2021 May 7.
7
Guidance on ambulatory blood pressure monitoring: A statement from the HOPE Asia Network.动态血压监测指南:HOPE 亚洲网络声明。
J Clin Hypertens (Greenwich). 2021 Mar;23(3):411-421. doi: 10.1111/jch.14128. Epub 2020 Dec 14.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验